Cachexia, malignancy and Tumor Necrosis Factor Alpha (Tnf-A)

Harefuah

Volumn 146, Issue 5, 2007, Pages 349-351

  Nussinovitch, U ^a,b   Shoenfeld, Y ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cachexia; Malignancy; Tumer Necrosis Factor (TNF) alpha

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

CACHEXIA; EDITORIAL; HUMAN; METASTASIS; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

CACHEXIA; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548641281     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Tisdale MJ, Molecular pathways leading to cancer cachexia. Physiology (Bethesda), 2005; 20: 340-8.
2. Morley JE, Thomas DR & Wilson MM, Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr, 2006; 83: 735-43.
3. Gordon JN, Green SR & Goggin PM, Cancer cachexia. Qjm, 2005; 98: 779-88.
4. Saini A, Nasser AS & Stewart CE, Waste management - cytokines, growth factors and cachexia. Cytokine Growth Factor Rev, 2006; 17: 475-86.
5. Baracos VE, Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr, 2006; 26: 435-61.
6. von Haehling S, Doehner W & Anker SD, Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res, 2007; 73: 298-309.
7. Argiles JM, Busquet S & Carcia Martinez C, Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition, 2005; 21: 977-85.
8. Rall LC & Roubenoff R, Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford), 2004; 43: 1219-23.
9. Camps C, Iranzo V & Bremnes RM, Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway. Support Care Cancer, 2006; 14: 1173-83.
10. Balkwill F, TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev, 2006; 25: 409-16.
11. Jatoi A, Egner J & Loprinzi CL, Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/ weight loss trial. Support Care Cancer, 2004; 12: 640-4.
12. Michalaki V, Syrigos KN & Charles P, Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer, 2004; 90: 2312-6.
13. Karayiannakis AJ, Syrigos KN & Polychronidis A, Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res, 2001; 21: 1355-8.
14. Walsmith J, Abad L & Kehayias J, Tumor necrosis factor-alpha production is associated with less body cell mass in women with rheumatoid arthritis. J Rheumatol, 2004; 31: 23-9.
15. Walsmith J & Roubenoff R, Cachexia in rheumatoid arthritis. Int J Cardiol, 2002; 85: 89-99.
16. Kotler DP, Cachexia. Ann Intern Med, 2000; 133: 622-34.
17. Argiles JM, Almendro V & Busquets S, The pharmacological treatment of cachexia. Curr Drug Targets, 2004; 5: 265-77.
18. Loprinzi CL, Schaid DY & Dose MA, Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol, 1993; 11: 152-4.
19. Beck SA & Tisdale MJ, Effect of insulin on weight loss and tumour growth in a cachexia model. Br J Cancer, 1989; 59: 677-81.
20. Han J, Thompson P & Beutler B, Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med, 1990; 172: 391-4.
21. Costelli P, Llovera M & Carbo N, Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Lett, 1995; 95: 33-8.
22. Goldberg RM, Loprinzi CL & Mailliard JA, Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol, 1995; 13: 2856-9.
23. Klausner JD, Makonkawkeyoon S & Akarasewi P, The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol, 1996; 11: 247-57.
24. Jatoi A, Jett JR & Sloan J, A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. Support Care Cancer, 2004; 12: 859-63.
25. Marcora SM, Chester KR & Mittal G, Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr, 2006; 84: 1463-72.
26. Briot K, Garnero P & Le Henanff A, Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment. Ann Rheum Dis, 2005; 64: 1137-40.
27. Sharma R & Anker SD, Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol, 2002; 85: 161-71.
28. Deswal A, Bozkurt B & Seta Y, Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation, 1999; 99: 3224-6.
29. Anker SD & Coats AJ, How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol, 2002; 86: 123-30.
30. Ting PT & Koo JY, Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol, 2006; 45: 689-92.
31. Clark MA, Plank LD & Connolly AB, Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis - a randomized, clinical trial. Crit Care Med, 1998; 26: 1650-9.
32. Dalum I, Butler DM & Jeusen MR, Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol, 1999; 17: 666-9.
33. Ghezzi P & Cerami A, Tumor necrosis factor as a pharmacological target. Mol Biotechnol, 2005; 31: 239-44.
34. Keane J, Gershon S & Wise RP, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med, 2001; 345: 1098-104.
35. Wolf F & Michaud K, Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum, 2004; 50: 1740-51.